• 23 March 2018

    Is IL-23 the new hot target for Psoriasis?

    On March 21, the FDA approved Sun Pharma’s Ilumya (tildrakizumab) for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy....